Literature DB >> 26104064

Health-related quality of life in patients with idiopathic normal pressure hydrocephalus.

A Junkkari1, H Sintonen2, O Nerg3,4, A M Koivisto3,4, R P Roine5,6, H Viinamäki7, H Soininen3,4, J E Jääskeläinen1, V Leinonen1.   

Abstract

BACKGROUND AND
PURPOSE: Factors affecting health-related quality of life (HRQoL) were explored in patients with idiopathic normal pressure hydrocephalus (iNPH).
METHODS: Using the 15D instrument HRQoL was evaluated in 132 patients diagnosed with iNPH by clinical and neuroradiological examinations. The severity of iNPH symptoms was measured with the iNPH grading scale (iNPHGS), depressive symptoms with the Beck Depression Inventory (BDI-21) and cognitive impairment with the Mini-Mental State Examination.
RESULTS: The mean (SD) 15D score (on a 0-1 scale) of patients with iNPH was significantly lower than that of an age- and gender-matched sample of the general population [0.718 (0.103) vs. 0.870 (0.106); P < 0.001]. The mean 15D score was lower in iNPH patients with moderate or severe depressive symptoms than in patients without depressive symptoms (P = 0.003). According to stepwise multiple linear regression analysis, a higher total iNPHGS score (b = -0.62, P < 0.001) and a higher BDI-21 total score (β = -0.201, P = 0.025) predicted a lower 15D score; in combination, these explained 51% of the variance in the 15D score (R(2)  = 0.506, P < 0.001).
CONCLUSIONS: Idiopathic normal pressure hydrocephalus impairs patients' HRQoL on multiple dimensions, similarly to other chronic diseases. Potentially treatable depressive symptoms contribute greatly to the HRQoL impairment of iNPH patients, but only if they are moderate or severe. The 15D portrayed HRQoL dimensions affected by iNPH in a similar way to broader assessment batteries and thus is a potentially useful tool for treatment evaluation and cost-utility analysis.
© 2015 EAN.

Entities:  

Keywords:  15D; Beck Depression Inventory; Mini-Mental State Examination; cognition impairment; depression; health-related quality of life; normal-pressure hydrocephalus

Mesh:

Year:  2015        PMID: 26104064     DOI: 10.1111/ene.12755

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  5 in total

1.  Shunt surgery in idiopathic normal pressure hydrocephalus is cost-effective-a cost utility analysis.

Authors:  Mats Tullberg; Josefine Persson; Jakob Petersen; Per Hellström; Carsten Wikkelsø; Åsa Lundgren-Nilsson
Journal:  Acta Neurochir (Wien)       Date:  2017-11-17       Impact factor: 2.216

2.  Incidental findings of typical iNPH imaging signs in asymptomatic subjects with subclinical cognitive decline.

Authors:  Doortje C Engel; Lukas Pirpamer; Edith Hofer; Reinhold Schmidt; Cornelia Brendle
Journal:  Fluids Barriers CNS       Date:  2021-08-14

3.  Gait, falls, cognitive function, and health-related quality of life after shunt-treated idiopathic normal pressure hydrocephalus-a single-center study.

Authors:  Caroline Hallqvist; Helena Grönstedt; Lisa Arvidsson
Journal:  Acta Neurochir (Wien)       Date:  2022-07-13       Impact factor: 2.816

4.  Diabetes is associated with familial idiopathic normal pressure hydrocephalus: a case-control comparison with family members.

Authors:  Joel Räsänen; Joel Huovinen; Ville E Korhonen; Antti Junkkari; Sami Kastinen; Simo Komulainen; Minna Oinas; Cecilia Avellan; Janek Frantzen; Jaakko Rinne; Antti Ronkainen; Mikko Kauppinen; Kimmo Lönnrot; Markus Perola; Anne M Koivisto; Anne M Remes; Hilkka Soininen; Mikko Hiltunen; Seppo Helisalmi; Mitja I Kurki; Juha E Jääskeläinen; Ville Leinonen
Journal:  Fluids Barriers CNS       Date:  2020-09-15

5.  Alterations in mitochondria-endoplasmic reticulum connectivity in human brain biopsies from idiopathic normal pressure hydrocephalus patients.

Authors:  Nuno Santos Leal; Giacomo Dentoni; Bernadette Schreiner; Olli-Pekka Kämäräinen; Nelli Partanen; Sanna-Kaisa Herukka; Anne M Koivisto; Mikko Hiltunen; Tuomas Rauramaa; Ville Leinonen; Maria Ankarcrona
Journal:  Acta Neuropathol Commun       Date:  2018-10-01       Impact factor: 7.801

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.